Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury
- PMID: 1353624
- DOI: 10.1016/0304-3940(92)90040-e
Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury
Abstract
After central nervous system (CNS) trauma, there are marked elevations in the extracellular levels of excitatory amino acids (EAA), which are believed to contribute to delayed tissue damage. Administration of N-methyl-D-aspartate (NMDA) receptor antagonists reduces injury severity after brain or spinal cord trauma, presumably by blocking the postsynaptic NMDA receptor. In the present studies, levels of extracellular amino acids were monitored by microdialysis during, and after, a moderately severe fluid-percussion brain injury to rats. Pretreatment (15 min prior to injury) with the non-competitive NMDA antagonist dextrorphan or the competitive NMDA antagonist CGS 19755 significantly attenuated the post-traumatic increase in extracellular glutamate. Pretreatment with dextrorphan attenuated the post-traumatic increase in extracellular levels of aspartate; although these differences did not reach significance when examined as absolute values, they were significant when analyzed as percent increase over pre-trauma baseline levels. These results are consistent with recent experiments and suggest that NMDA antagonists may limit the release of glutamate and aspartate after trauma through a presynaptic mechanism.
Similar articles
-
The role of excitatory amino acids and NMDA receptors in traumatic brain injury.Science. 1989 May 19;244(4906):798-800. doi: 10.1126/science.2567056. Science. 1989. PMID: 2567056
-
Regulation of excitatory amino acid release by N-methyl-D-aspartate receptors in rat striatum: in vivo microdialysis studies.Brain Res. 1992 Jul 10;585(1-2):105-15. doi: 10.1016/0006-8993(92)91195-k. Brain Res. 1992. PMID: 1355000
-
Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury.Eur J Pharmacol. 1990 Jan 10;175(2):165-74. doi: 10.1016/0014-2999(90)90227-w. Eur J Pharmacol. 1990. PMID: 2155794
-
[Role of excitatory amino acids in neuropathology].Medicina (B Aires). 1995;55(4):355-65. Medicina (B Aires). 1995. PMID: 8728878 Review. Spanish.
-
The role of glutamate in epilepsy and other CNS disorders.Neurology. 1994 Nov;44(11 Suppl 8):S14-23. Neurology. 1994. PMID: 7970002 Review.
Cited by
-
Selective CDK inhibitors: promising candidates for future clinical traumatic brain injury trials.Neural Regen Res. 2014 Sep 1;9(17):1578-80. doi: 10.4103/1673-5374.141779. Neural Regen Res. 2014. PMID: 25368642 Free PMC article. Review.
-
Cyclopropyl-containing positive allosteric modulators of metabotropic glutamate receptor subtype 5.Bioorg Med Chem Lett. 2015 Jun 1;25(11):2275-9. doi: 10.1016/j.bmcl.2015.04.042. Epub 2015 Apr 20. Bioorg Med Chem Lett. 2015. PMID: 25937015 Free PMC article.
-
Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice.PLoS One. 2013;8(3):e57208. doi: 10.1371/journal.pone.0057208. Epub 2013 Mar 28. PLoS One. 2013. PMID: 23555560 Free PMC article.
-
Acyl-2-aminobenzimidazoles: a novel class of neuroprotective agents targeting mGluR5.Bioorg Med Chem. 2015 May 1;23(9):2211-20. doi: 10.1016/j.bmc.2015.02.054. Epub 2015 Mar 6. Bioorg Med Chem. 2015. PMID: 25801156 Free PMC article.
-
Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery.Pharmaceutics. 2022 Aug 2;14(8):1609. doi: 10.3390/pharmaceutics14081609. Pharmaceutics. 2022. PMID: 36015236 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources